乳腺癌Ⅰ、Ⅱ组淋巴结Ki67定性、定量表达差异及相关分析

阳宁静; 任静; 李吉满; 阳宁静; 任静; 李吉满

doi:10.13898/j.cnki.issn.1000-2200.2018.09.002

[1]

孝平.外科学[M].北京:人民卫生出版社,2002:429.

[2]

YAMASHITA H,OGIYA A,SHIEN T,et al.Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive,HER2-negative breast cancer[J].Breast Cancer,2016,23(6):830.

[3]

COSTA OF NETO,CASTRO RB,OLIVEIRA CV,et al.Predictive factors of axillary metastasis in patients with breast cancer and positive sentinel lymph node biopsy[J].Rev Col Bras Cir,2017,44(4):391.

[4]

DUFFY MJ,HARBECK N,NAP M,et al.Clinical use of biomarkers in breast cancer:updated guidelines from the European Group on Tumor Markers (EGTM)[J].Eur J Cancer,2017,75:284.

[5]

ÁCS B,KULKA J,KOVÁCS KA,et al.Comparison of 5 Ki-67 antibodies regarding reproducibility and capacity to predict prognosis in breast cancer:does the antibody matter?[J].Hum Pathol,2017,65:31.

[6]

GOLDHIRSCH A,WOOD WC,COATES AS,et al.Strategies for subtypes:dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy ofEarly Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736.

[7]

刘勇,杨海玉.2015版美国癌症协会乳腺癌筛查指南解读[J].中华肿瘤防治杂志,2016,23(4):275.

[8]

SHANDIZ FH,SHABAHANG H,AFZALJAVAN F,et al.Ki67 frequency in breast cancers without axillary lymph node involvement and its relation with disease-free survival[J].Asian Pac J Cancer Prev,2016,17(3):1347.

[9]

HU Y,GU R,ZHAO J,et al.Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2- breast cancers by the 2015 St.Gallen consensus classification[J].BMC Cancer,2017,17(1):28.

[10]

刘广舒,高云,郭鹏,等.C-erbB-2、Ki67、nm23基因表达与乳腺癌腋窝淋巴结转移的相关性分析[J].实用预防医学,2013,20(3):340.

[11]

马榕.乳腺癌改良根治术中清扫腋窝Ⅲ组淋巴结的经验与技巧[J].中国实用外科杂志,2006,26(4):298.

[12]

ADACHI Y,SAWAKI M,HATTORI M,et al.Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma[J].Breast Cancer,2018,25(5):560.

[13]

PATANI N,MOKBEL K.Clinical significance of sentinel lymph node isolated tumour cells in breast cancer[J].Breast Cancer Res Treat,2011,127(2):325.

[14]

王建法,顾超,叶宣光.乳腺癌淋巴结转移与Ki67、VEGF表达的相关性及其临床意义[J].实用癌症杂志,2009,24(5):450.

[15]

夏银娣,朱慧庭,王庆,等.乳腺癌患者Ki67指数的临床意义[J].中国医刊,2017,52(1):68.

[16]

KONDOV B,KONDOV G,SPIROVSKI Z,et al.Prognostic factors on the positivity for metastases of the axillary lymph nodes from primary breast cancer[J].Pril (Makedon Akad Nauk Umet Odd Med Nauki),2017,38(1):81.

[17]

SCHNEIDER J,POLLÁN M,RUIBAL A,et al.Histologic grade and CD44 are independent predictors of axillary lymph node invasion in early (T1) breast cancer[J].Tumour Biol,1999,20(6):319.

[18]

CONNOLLY JL.Changes and problematic areas in interpretation of the AJCC Cancer Staging Manual,6th Edition,for breast cancer[J].Arch Pathol Lab Med,2006,130(3):287.

[19]

SINGLETARY SE,ALLRED C,ASHLEY P,et al.Revision of the American joint committee on cancer staging system for breast cancer[J].J Clin Oncol,2002,20:3628.

[20]

ILLYES I,TOKES AM,KOVACS A,et al.In breast cancer patients sentinel lymph node metastasis characteristics predict further axillary involvement[J].Virchows Arch,2014,465(1):15.

[21]

KHAFAGY M,MOSTAFA A,FAKHR I.Distribution of axillary lymph node metastases in different levels and groups in breast cancer,a pathological study[J].J Egypt Natl Canc Inst,2011,23(1):25.